Brainomix 360 e-Lung: Vision to Precision

Brainomix 360 e-Lung is an imaging software that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD), powered by novel, proprietary technology.

With a recent expansion of its FDA clearance, the next generation e-Lung technology represents a significant step forward for the care of patients with ILD, with improved AI and machine learning (ML) algorithms, and a longitudinal assessment functionality that enables clinicians to more easily track results across multiple scan timepoints.

Robust Validation: INBUILD Trial

Through a research collaboration with Boehringer Ingelheim, the global leader in pulmonary fibrosis therapies, Brainomix were granted privileged access to the landmark INBUILD clinical trial dataset to run the first quantitative CT analysis.

The results firmly validate e-Lung as a reliable tool for identifying progressive pulmonary fibrosis accurately and sensitively, while also demonstrating its prognostic accuracy in identifying patients at risk of progressive pulmonary fibrosis.

“The imaging data presented at ATS 2025 from our INBUILD clinical trial in patients with progressive pulmonary fibrosis are part of a collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy and ultimately patient care," Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim.

e-Lung: Advancing Lung Disease Care

Pulmonary fibrosis is a subset of Interstitial Lung Diseases (ILDs), and a chronic lung condition that is progressive and life-limiting. Untreated, patients can have a lifespan as short as three to five years from diagnosis, and yet despite this, often wait up to two years to be diagnosed.

The key to the best outcome and survival for patients with pulmonary fibrosis is early initiation of treatment. However, identifying patients eligible for treatment based on imaging can be challenging, even for experts.

“e-Lung is a powerful tool, more sensitive to progression than visual analysis and more accurate than lung function change. This ability to accurately identify serial change can help physicians to make better treatment decisions at an earlier time point. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up, and to escalate their care in a more timely manner,” Dr Peter George, Consultant Pulmonologist at the Royal Brompton & Brainomix Medical Director.

Brainomix AI-powered lung imaging biomarkers are available now for use in clinical trials to:

Objectively assess treatment response

Predict disease behavior and outcomes from baseline imaging

Explore and characterize responsive phenotypes

Hear from our valued partners and collaborators

TIPAL Study

Norwich, UK

"It is great to have the chance to incorporate the cutting-edge CT scanning technology, e-Lung, developed by Brainomix into the TIPAL study."

Elizabeth Estes

OSIC Executive Director

"Brainomix's history of establishing successful collaborations, and their expertise in AI imaging biomarkers, certainly brings positive momentum to OSIC."

Bridge Biotherapeutics

Seoul, South Korea

“We believe that the partnership with Brainomix will enable us to generate supplemental efficacy data from our clinical study on IPF patients based on their combined imaging technology and expertise. We expect to gain further insights, including earlier prediction of treatment response in patients.”

OSIC

Chicago, USA

“We are pleased to see these encouraging data and developments from Brainomix as they highlight the important value of our consortium in enabling the development of novel solutions to combat Pulmonary Fibrosis.”